JP2000516965A5 - - Google Patents

Download PDF

Info

Publication number
JP2000516965A5
JP2000516965A5 JP1999501622A JP50162299A JP2000516965A5 JP 2000516965 A5 JP2000516965 A5 JP 2000516965A5 JP 1999501622 A JP1999501622 A JP 1999501622A JP 50162299 A JP50162299 A JP 50162299A JP 2000516965 A5 JP2000516965 A5 JP 2000516965A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1999501622A
Other languages
English (en)
Japanese (ja)
Other versions
JP4380802B2 (ja
JP2000516965A (ja
Filing date
Publication date
Priority claimed from GB9712434A external-priority patent/GB2326334A/en
Application filed filed Critical
Publication of JP2000516965A publication Critical patent/JP2000516965A/ja
Publication of JP2000516965A5 publication Critical patent/JP2000516965A5/ja
Application granted granted Critical
Publication of JP4380802B2 publication Critical patent/JP4380802B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP50162299A 1997-06-13 1998-06-10 医薬用エアロゾル組成物 Expired - Lifetime JP4380802B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9712434.1 1997-06-13
GB9712434A GB2326334A (en) 1997-06-13 1997-06-13 Pharmaceutical aerosol compositions
PCT/EP1998/003533 WO1998056349A1 (en) 1997-06-13 1998-06-10 Pharmaceutical aerosol composition

Publications (3)

Publication Number Publication Date
JP2000516965A JP2000516965A (ja) 2000-12-19
JP2000516965A5 true JP2000516965A5 (enExample) 2005-12-08
JP4380802B2 JP4380802B2 (ja) 2009-12-09

Family

ID=10814179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50162299A Expired - Lifetime JP4380802B2 (ja) 1997-06-13 1998-06-10 医薬用エアロゾル組成物

Country Status (44)

Country Link
EP (2) EP0920302B2 (enExample)
JP (1) JP4380802B2 (enExample)
KR (1) KR100546239B1 (enExample)
CN (1) CN1138532C (enExample)
AR (1) AR012977A1 (enExample)
AT (1) ATE222751T1 (enExample)
AU (1) AU729966B2 (enExample)
BG (1) BG63906B1 (enExample)
BR (1) BR9805993B1 (enExample)
CA (1) CA2263445C (enExample)
CO (1) CO4940408A1 (enExample)
CZ (1) CZ295521B6 (enExample)
DE (1) DE69807420T3 (enExample)
DK (1) DK0920302T4 (enExample)
DZ (1) DZ2516A1 (enExample)
EA (1) EA001259B1 (enExample)
EE (1) EE03664B1 (enExample)
ES (1) ES2182351T5 (enExample)
GB (1) GB2326334A (enExample)
GE (1) GEP20012462B (enExample)
HR (1) HRP980317B1 (enExample)
HU (1) HU228487B1 (enExample)
ID (1) ID21491A (enExample)
IL (1) IL128484A (enExample)
IN (1) IN189317B (enExample)
IS (1) IS2435B (enExample)
IT (1) IT1293803B1 (enExample)
MA (1) MA26507A1 (enExample)
ME (2) ME00333B (enExample)
MY (1) MY119074A (enExample)
NO (1) NO327775B1 (enExample)
NZ (1) NZ334149A (enExample)
PL (1) PL193721B1 (enExample)
PT (1) PT920302E (enExample)
RS (1) RS51274B (enExample)
SA (1) SA98190821B1 (enExample)
SI (1) SI0920302T2 (enExample)
SK (1) SK284430B6 (enExample)
TN (1) TNSN98087A1 (enExample)
TR (1) TR199900288T1 (enExample)
TW (1) TW555570B (enExample)
UA (1) UA70289C2 (enExample)
WO (1) WO1998056349A1 (enExample)
ZA (1) ZA985136B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
ES2274803T3 (es) 1999-09-11 2007-06-01 Glaxo Group Limited Formulacion farmaceutica de propionato de fluticasona.
EP1231894B1 (en) * 1999-11-23 2005-01-12 Glaxo Group Limited Pharmaceutical formulations of salmeterol
US20030032632A1 (en) * 1999-12-24 2003-02-13 Crispps Leslie Alan Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
UA73986C2 (uk) * 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
WO2002072067A2 (en) * 2001-03-12 2002-09-19 Glaxo Group Limited Pharmaceutical aerosol formulation
ES2222294T3 (es) 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
EP3384931B1 (en) 2002-03-01 2019-07-24 Chiesi Farmaceutici S.p.A. Formoterol superfine formulation
EP1340503A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Solution aerosol formulation containing esters of 3, 17-dihydroxy oestratriene derivates for pulmonary delivery
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
DE10214263A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
EP1369113B1 (en) * 2002-06-06 2006-11-22 CHIESI FARMACEUTICI S.p.A. Solubilisation of drugs in HFA propellant by means of emulsions
AU2003293528A1 (en) * 2003-02-04 2004-09-06 Chrysalis Technologies Incorporated Perfluorocarbon and hydrofluorocarbon formulations and methods of making and using same
EP1915985A1 (en) 2003-03-20 2008-04-30 Boehringer Ingelheim Pharmaceuticals Inc. Formulation for a Metered Dose Inhaler Using Hydro-Fluoro-Alkanes as Propellants
ES2304616T3 (es) * 2003-03-20 2008-10-16 Boehringer Ingelheim Pharmaceuticals Inc. Formulacion para un inhalador con dosis medida utilizando hidro-fluoro-alcanos como propulsores.
SE0303179D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EA013428B1 (ru) 2004-07-02 2010-04-30 Бёрингер Ингельхайм Интернациональ Гмбх РАСПЫЛЯЕМЫЕ В ВИДЕ АЭРОЗОЛЯ СУСПЕНЗИОННЫЕ КОМПОЗИЦИИ С TG 227ea ИЛИ TG 134a В КАЧЕСТВЕ ПРОПЕЛЛЕНТА
DE102006017320A1 (de) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
GB0621707D0 (en) * 2006-10-31 2006-12-13 Univ London Pharmacy Formulations for delivery via pressurised metered dose inhalers
GB0712454D0 (en) 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
CA2704639A1 (en) * 2007-11-07 2009-05-14 Astrazeneca Ab Dry powder formulations comprising ascorbic acid derivates
RU2561833C2 (ru) * 2010-09-06 2015-09-10 Кьези Фармасьютичи С.П.А. Дозирующий ингалятор и способ его применения
JP5409594B2 (ja) * 2010-12-22 2014-02-05 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
JP6335798B2 (ja) 2012-02-28 2018-05-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規噴射剤含有チオトロピウム製剤
RU2504402C1 (ru) * 2012-11-20 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный состав в форме аэрозоля для лечения бронхиальной астмы и хронической обструктивной болезни легких
GB201402513D0 (en) 2014-02-13 2014-04-02 Cardiff Scintigraphics Ltd Pressurised metered dose inhalers and method of manufacture
EP3174522A1 (en) 2014-07-29 2017-06-07 3M Innovative Properties Company Method of preparing a pharmaceutical composition
MA43782A (fr) 2016-03-31 2021-04-28 Chiesi Farm Spa Dispositif d'inhalation d'aérosol
PH12019500577B1 (en) * 2016-09-19 2023-09-08 Mexichem Fluor Sa De Cv Pharmaceutical composition
WO2025039045A1 (en) * 2023-08-23 2025-02-27 Inhaler Supplies Pty Ltd Inhalable formulation for volatile actives

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2038696T3 (es) † 1986-03-10 1996-07-16 Burghart Kurt Procedimiento para producir un preparado farmaceutico.
DE3767615D1 (de) † 1986-03-10 1991-02-28 Kurt Burghart Pharmazeutikum sowie verfahren zu seiner herstellung.
US4899874A (en) † 1988-04-26 1990-02-13 Rehrig-Pacific Company, Inc. Stackable low depth bottle case
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) † 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
DE3905726A1 (de) * 1989-02-24 1990-08-30 Hoechst Ag Druckgaspackung und treibmittel fuer aerosole
EP0553298B1 (en) † 1990-10-18 1994-11-17 Minnesota Mining And Manufacturing Company Aerosol formulation comprising beclomethasone 17,21 dipropionate
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
ATE339952T1 (de) * 1991-06-10 2006-10-15 Schering Corp Fluorchlorkohlenwasserstofffreie aerosolformulierungen
DK0656206T3 (da) † 1991-06-10 2001-10-08 Schering Corp Aerosolformuleringer uden chlorfluorcarbonforbindelser
DE4123663A1 (de) * 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Aerosol-zubereitung und verwendung eines treibmittels dafuer
DE4123668A1 (de) * 1991-07-17 1993-01-21 Rovema Gmbh Verfahren und vorrichtung zur zufuehrung von folienmaterial zu einer intermittierend arbeitenden schlauchbeutelmaschine
DE69205177T2 (de) * 1991-12-12 1996-03-21 Glaxo Group Ltd., Greenford, Middlesex Pharmazeutische Aerosolformulierung.
JP3908269B2 (ja) * 1991-12-18 2007-04-25 スリーエム カンパニー 懸濁エアゾール製剤
WO1994013263A1 (en) * 1992-12-09 1994-06-23 Jager Paul D Stabilized medicinal aerosol solution formulations
US5502076A (en) * 1994-03-08 1996-03-26 Hoffmann-La Roche Inc. Dispersing agents for use with hydrofluoroalkane propellants
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
US5534242A (en) † 1994-05-02 1996-07-09 Henry; Richard A. Lidocaine-vasoconstrictor aerosol preparation
CA2189351C (en) † 1994-05-13 2008-12-30 Stephen J. Farr Narcotic containing aerosol formulation
US5653961A (en) † 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
US5635161A (en) † 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
GB9517998D0 (en) † 1995-09-04 1995-11-08 Bioglan Lab Ltd Compositions and device for their administration
JP2000514085A (ja) * 1996-07-08 2000-10-24 ローヌ―プーラン・ロウラー・リミテッド 医薬シクロスポリンａエーロゾル溶液処方物
WO1998024420A1 (en) † 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Pharmaceutical compositions and devices for their administration
EP1014943B1 (de) † 1997-02-05 2002-06-19 Jago Research Ag Medizinische aerosolformulierungen

Similar Documents

Publication Publication Date Title
JP2000509942A5 (enExample)
JP2000507042A5 (enExample)
JP2000509637A5 (enExample)
JP2000509635A5 (enExample)
JP2000509912A5 (enExample)
JP2000510751A5 (enExample)
JP2000509587A5 (enExample)
JP2000507369A5 (enExample)
JP2000507433A5 (enExample)
JP2000508866A5 (enExample)
JP2000510793A5 (enExample)
JP2000508022A5 (enExample)
JP2000508841A5 (enExample)
JP2000508680A5 (enExample)
JP2000509804A5 (enExample)
JP2000509853A5 (enExample)
JP2000509755A5 (enExample)
JP2000510247A5 (enExample)
JP2000510969A5 (enExample)
JP2000508836A5 (enExample)
JP2000508102A5 (enExample)
JP2000509818A5 (enExample)
JP2000509520A5 (enExample)
JP2000507434A5 (enExample)
JP2000508880A5 (enExample)